Persistence of Mucosal T-cell Responses to Herpes Simplex Virus Type 2 in the Female Genital Tract

Overview

Journal Mucosal Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2014 Jun 12

PMID 24917455

Citations 26

Authors

C M Posavad

L Zhao

D E Mueller

C E Stevens

M L Huang

A Wald

L Corey

Affiliations

Soon will be listed here.

Abstract

Relatively little is known about the human T-cell response to herpes simplex virus type 2 (HSV-2) in the female genital tract, a major site of heterosexual HSV-2 acquisition, transmission, and reactivation. In order to understand the role of local mucosal immunity in HSV-2 infection, T-cell lines were expanded from serial cervical cytobrush samples from 30 HSV-2-infected women and examined for reactivity to HSV-2. Approximately 3% of the CD3+ T cells isolated from the cervix were HSV-2 specific and of these, a median of 91.3% were CD4+, whereas a median of 3.9% were CD8+. HSV-2-specific CD4+ T cells expanded from the cervix were not only more frequent than CD8+ T cells but also exhibited greater breadth in terms of antigenic reactivity. T cells directed at the same HSV-2 protein were often detected in serial cervical cytobrush samples and in blood. Thus, broad and persistent mucosal T-cell responses to HSV-2 were detected in the female genital tract of HSV-2+ women suggesting that these cells are resident at the site of HSV-2 infection. Understanding the role of these T cells at this biologically relevant site will be central to the elucidation of adaptive immune mechanisms involved in controlling HSV-2 disease.

Citing Articles

NET-EN treatment leads to delayed HSV-2 infection, enhanced mucin and T cell functions in the female genital tract when compared to DMPA in a preclinical mouse model.

Mian M, Pa S, Rahman N, Gillgrass A, Kaushic C Front Immunol. 2024; 15:1427842.

PMID: 39569191 PMC: 11576457. DOI: 10.3389/fimmu.2024.1427842.

Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.

Yount K, Darville T Vaccines (Basel). 2024; 12(8).

PMID: 39203989 PMC: 11359697. DOI: 10.3390/vaccines12080863.

Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.

Bourne N, Keith C, Miller A, Pyles R, Cohen G, Milligan G J Virol. 2023; 97(9):e0066923.

PMID: 37655939 PMC: 10537585. DOI: 10.1128/jvi.00669-23.

Immunomodulatory Role of Interferons in Viral and Bacterial Infections.

Mertowska P, Smolak K, Mertowski S, Grywalska E Int J Mol Sci. 2023; 24(12).

PMID: 37373262 PMC: 10298684. DOI: 10.3390/ijms241210115.

Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.

Awasthi S, Onishi M, Lubinski J, Fowler B, Naughton A, Hook L Viruses. 2023; 15(5).

PMID: 37243234 PMC: 10220834. DOI: 10.3390/v15051148.

References

Peng T, Zhu J, Phasouk K, Koelle D, Wald A, Corey L . An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J Virol. 2012; 86(19):10587-96. PMC: 3457322. DOI: 10.1128/JVI.01237-12. View

John M, Keller M, Fam E, Cheshenko N, Hogarty K, Kasowitz A . Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005; 192(10):1731-40. DOI: 10.1086/497168. View

Johansson E, Rudin A, Wassen L, Holmgren J . Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 1999; 96(2):272-7. PMC: 2326729. DOI: 10.1046/j.1365-2567.1999.00675.x. View

Bagdades E, Pillay D, Squire S, ONeil C, Johnson M, Griffiths P . Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS. 1992; 6(11):1317-20. DOI: 10.1097/00002030-199211000-00012. View

Hosken N, McGowan P, Meier A, Koelle D, Sleath P, Wagener F . Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol. 2006; 80(11):5509-15. PMC: 1472180. DOI: 10.1128/JVI.02659-05. View

Posavad C, Wald A, Hosken N, Huang M, Koelle D, Ashley R . T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?. J Immunol. 2003; 170(8):4380-8. DOI: 10.4049/jimmunol.170.8.4380. View

Keller M, Madan R, Shust G, Carpenter C, Torres N, Cho S . Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr. 2012; 61(2):194-202. PMC: 3685489. DOI: 10.1097/QAI.0b013e31826867ae. View

Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y . Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007; 323(1):39-54. PMC: 2683732. DOI: 10.1016/j.jim.2007.03.002. View

Bere A, Denny L, Burgers W, Passmore J . Polyclonal expansion of cervical cytobrush-derived T cells to investigate HIV-specific responses in the female genital tract. Immunology. 2010; 130(1):23-33. PMC: 2855790. DOI: 10.1111/j.1365-2567.2009.03172.x. View

10.

Freeman E, Weiss H, Glynn J, Cross P, Whitworth J, Hayes R . Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2005; 20(1):73-83. DOI: 10.1097/01.aids.0000198081.09337.a7. View

11.

Ouwendijk W, Laing K, Verjans G, Koelle D . T-cell immunity to human alphaherpesviruses. Curr Opin Virol. 2013; 3(4):452-60. PMC: 3748210. DOI: 10.1016/j.coviro.2013.04.004. View

12.

Koelle D, Abbo H, Peck A, Ziegweid K, Corey L . Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis. 1994; 169(5):956-61. DOI: 10.1093/infdis/169.5.956. View

13.

Gupta R, Warren T, Wald A . Genital herpes. Lancet. 2007; 370(9605):2127-37. DOI: 10.1016/S0140-6736(07)61908-4. View

14.

Jing L, Haas J, Chong T, Bruckner J, Dann G, Dong L . Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest. 2012; 122(2):654-73. PMC: 3266794. DOI: 10.1172/JCI60556. View

15.

Moodie Z, Huang Y, Gu L, Hural J, Self S . Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods. 2006; 315(1-2):121-32. DOI: 10.1016/j.jim.2006.07.015. View

16.

Levine W, Pope V, Bhoomkar A, Tambe P, Lewis J, Zaidi A . Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis. 1998; 177(1):167-74. DOI: 10.1086/513820. View

17.

Koelle D, Chen H, GAVIN M, Wald A, Kwok W, Corey L . CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol. 2001; 166(6):4049-58. DOI: 10.4049/jimmunol.166.6.4049. View

18.

Bere A, Denny L, Hanekom W, Burgers W, Passmore J . Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women. J Immunol Methods. 2010; 354(1-2):68-79. PMC: 2854893. DOI: 10.1016/j.jim.2010.02.002. View

19.

Posavad C, Huang M, Barcy S, Koelle D, Corey L . Long term persistence of herpes simplex virus-specific CD8+ CTL in persons with frequently recurring genital herpes. J Immunol. 2000; 165(2):1146-52. DOI: 10.4049/jimmunol.165.2.1146. View

20.

Johnston C, Koelle D, Wald A . HSV-2: in pursuit of a vaccine. J Clin Invest. 2011; 121(12):4600-9. PMC: 3223069. DOI: 10.1172/JCI57148. View